Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Monoclonal antibodies for the treatment of adult ALL

Usman Ali Akbar • 19 Apr 2022
The 2022 Tandem Meetings
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Usman Ali Akbar, MBBS, University of Louisville, Louisville, KY, talks on the efficacy of monoclonal antibodies in the treatment of adult acute lymphoblastic leukemia (ALL). Dr Akbar explains that monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin are more effective than standard of care (SOC) chemotherapy. However, more clinical trials are needed to evaluate the safety and efficacy of these antibodies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Usman Ali Akbar

Safety and efficacy of new TKIs in Ph+ ALL
1:17
Safety and efficacy of new TKIs in Ph+ ALL
Usman Ali Akbar • 19 Apr 2022
Can alloHSCT be avoided in Ph+ ALL?
0:52
Can alloHSCT be avoided in Ph+ ALL?
Usman Ali Akbar • 19 Apr 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals